Chargement en cours...
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type
Due to frequent phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway dysregulation, AKT is typically accepted as a promising anticancer therapeutic target. mTOR, in particular, represents a suitable therapeutic target for hepatocellular carcinoma, whilst suppre...
Enregistré dans:
| Publié dans: | Oncol Lett |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4774473/ https://ncbi.nlm.nih.gov/pubmed/26998062 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4111 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|